Literature DB >> 18377819

Liver transplant in patients with HIV: infection risk associated with HIV and post-transplant immunosuppression.

Pierluigi Viale1, Umberto Baccarani, Marcello Tavio.   

Abstract

Before the introduction of highly active antiretroviral therapy, HIV-infected patients who underwent liver transplantation (LT) had poor survival, mainly because of a rapid progression to AIDS and its infectious complications during the post-LT immunosuppression phase. However, in the era of highly active antiretroviral therapy, under some specific and well-determined conditions, LT might be as safe and efficacious in HIV patients as it is in non-HIV-infected patients. End-stage liver failure as caused by hepatitis B virus, cirrhosis, and hepatotoxicity should be considered indications for LT in every transplant center. Because of the almost universal hepatitis C virus reinfection and its accelerated course post-LT, LT in hepatitis C virus-coinfected patients deserves more caution and more extended follow-up before it is accepted as a standard indication for LT in HIV-infected patients.

Entities:  

Year:  2008        PMID: 18377819     DOI: 10.1007/s11908-008-0013-z

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  50 in total

1.  Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels.

Authors:  A M Sheikh; D C Wolf; E Lebovics; R Goldberg; H W Horowitz
Journal:  Transplantation       Date:  1999-07-27       Impact factor: 4.939

2.  Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV).

Authors:  R Schvarcz; G Rudbeck; G Söderdahl; L Ståhle
Journal:  Transplantation       Date:  2000-05-27       Impact factor: 4.939

3.  Liver transplantation for an HIV-positive patient in the era of highly active antiretroviral therapy.

Authors:  P J Gow; D Mutimer
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

4.  Long-term survival without immunosuppression in HIV-positive liver-graft recipient.

Authors:  P Vanhems; S Bresson-Hadni; D A Vuitton; J P Miguet; M Gillet; M Lab; C Brechot
Journal:  Lancet       Date:  1991-01-12       Impact factor: 79.321

5.  [Orthotopic liver transplantation in a 33-year-old patient with fulminant hepatitis B and HIV infection].

Authors:  K Schliefer; W D Paar; G Aydemir; M Wolff; J K Rockstroh; U Spengler; T Sauerbruch
Journal:  Dtsch Med Wochenschr       Date:  2000-04-28       Impact factor: 0.628

Review 6.  Hepatitis C and HIV infection: biological, clinical, and therapeutic implications.

Authors:  V Soriano; J Garcìa-Samaniego; R Rodrìguez-Rosado; J Gonzàlez; J Pedreira
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

7.  [Liver transplantation in a patient infected by human immunodefficiency virus].

Authors:  Antoni Rafecas; Gabriel Rufí; Juan Fabregat; Xavier Xiol
Journal:  Med Clin (Barc)       Date:  2002-11-02       Impact factor: 1.725

8.  Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis.

Authors:  Klaus Radecke; Nils R Frühauf; Michael Miller; Birgit Ross; Roland Köditz; Massimo Malagó; Christoph E Broelsch; Guido Gerken; Ulrich Treichel
Journal:  Liver Int       Date:  2005-02       Impact factor: 5.828

9.  [Liver transplantation: is it possible in HIV/HCV co-infected patients?].

Authors:  D Vittecoq; E Teicher; M Merad; J Duclos Vallée; E Dussaix; D Samuel
Journal:  Pathol Biol (Paris)       Date:  2003-10

Review 10.  Transplantation in the HIV+ patient.

Authors:  P C Kuo; P G Stock
Journal:  Am J Transplant       Date:  2001-05       Impact factor: 8.086

View more
  1 in total

1.  Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era.

Authors:  Isaline Coquet; Juliette Pavie; Pierre Palmer; François Barbier; Stéphane Legriel; Julien Mayaux; Jean Michel Molina; Benoît Schlemmer; Elie Azoulay
Journal:  Crit Care       Date:  2010-06-09       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.